BioPharma Resources

Drug Trial Radar · NCT00924989

A Study of OSI-906 in Patients With Locally Advanced or Metastatic Adrenocortical Carcinoma

A Randomized, Double-blind, Placebo-controlled, Phase 3 Study of OSI-906 in Patients With Locally Advanced or Metastatic Adrenocortical Carcinoma

Last checked: Nov 19, 2026Latest source record: Nov 20, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 139 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

139

Actual

Start

Dec 1, 2009

Primary completion

Jul 11, 2012

Study completion Oct 8, 2012

Sponsor

Lead sponsor
Astellas Pharma IncAstellas (ALPMY)
Sponsor type
Industry
First posted
Jun 19, 2009

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A multicenter, randomized, double-blind, placebo-controlled, phase 3 study of single-agent OSI-906 in patients with locally advanced/metastatic Adrenocortical Carcinoma (ACC) who received at least 1 but no more than 2 prior drug regimens

Conditions

  • Adrenocortical Carcinoma

Interventions

  • OSI-906Drug

    Administered orally

  • PlaceboOther

    Matching placebo administered orally

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Overall survival of single agent OSI-906 versus placeboTime frame: 33 months

Locations

35 sites in 9 countries. Site status is shown where the registry gives one.

  • TGen Clinical Research Service at Scottsdale Healthcare

    Scottsdale, Arizona

  • University of Southern California

    Los Angeles, California

  • UCLA

    Los Angeles, California

  • University of Colorado Denver Cancer Center

    Aurora, Colorado

  • University of Miami

    Miami, Florida

  • Dana-Farber Cancer Institute

    Boston, Massachusetts

  • University of Michigan

    Ann Arbor, Michigan

  • Karmanos Cancer Institute

    Detroit, Michigan

  • Dartmouth Medical School

    Lebanon, New Hampshire

  • Duke Clinical Cancer Trials Services

    Durham, North Carolina

  • Ohio State University

    Columbus, Ohio

  • Vanderbilt University Medical Center

    Nashville, Tennessee

  • Mary Crowley Cancer Research Center

    Dallas, Texas

  • MD Anderson Cancer Center

    Houston, Texas

  • Royal North Shore Hospital Department of Endocrinology

    St Leonards, New South Wales, Australia

  • St. Joseph's Hospital

    Hamilton, Ontario, Canada

  • PMH - Princess Margaret Hospital

    Toronto, Ontario, Canada

  • Centre hospitalier de l'Université de Montréal (CHUM)

    Montreal, Quebec, Canada

  • CHRU Lille, Clinique Endocrinologique Marc Linquette

    Lille, France

  • Centre Léon Bérard

    Lyon, France

  • Institut Paoli-Calmettes

    Marseille, France

  • Hôpital Cochin-Saint Vincent de Paul

    Paris, France

  • CHU Bordeaux - Hôpital Haut-Lévêque

    Pessac, France

  • Institut Gustave Roussy

    Villejuif, France

  • Charite Universitaetsmedizin

    Berlin, Germany

  • LMU München

    Munich, Germany

  • Universitaets Klinikum Wuerzburg

    Würzburg, Germany

  • Universita di Torino

    Orbassano, Italy

  • Università Cattolica del Sacro Cuore

    Rome, Italy

  • Academic Medical Center

    Amsterdam, Netherlands

  • Maxima Medisch Centrum (MMC)

    Eindhoven, Netherlands

  • Erasmus MC Rotterdam

    Rotterdam, Netherlands

  • Centrum Onkologii Instytut im. Marii Sklodowskiej-Curie Oddzial w Gliwicach

    Gliwice, Poland

  • St. James' University hospital

    Leeds, United Kingdom

  • Royal Marsden NHS Trust

    London, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.